España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan ire healthcare limited - ibuprofeno - suspensiÓn oral - 20 mg/ml - ibuprofeno 20 mg - ibuprofeno

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ferring s.a. - desmopresina - gotas nasales en soluciÓn - 0,1 mg/ml - desmopresina 0,1 mg - desmopresina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ferring s.a. - desmopresina - solucion para pulverizacion nasal - 0,1 mg/ml - desmopresina 0,1 mg - desmopresina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ferring s.a. - desmopresina - solucion para pulverizacion nasal - 150 microgramos/ml - desmopresina 1,5 mg - desmopresina

Argentina - español - SANI (Asociación de Cooperativas Argentinas)

ruta seis s.a. - suspensión de virus rábico cepa pasteur desarrollada en células bhk 21 don 13inactivada con betapropiolactona y adyuvada con hidróxido de aluminio. cada mililitro contiene un mínimo de 1 ui de potencia. - suspensión de virus rábico cepa pasteur desarrollada en células bhk 21 don 13inactivada con betapropiolactona y adyuvada con hidróxido de aluminio. cada mililitro contiene un mínimo de 1 ui de potencia. - caninos; felinos

Argentina - español - SANI (Asociación de Cooperativas Argentinas)

ruta seis s.a. - suspensión de virus rábico cepa pasteur desarrollada en células bhk 21 don 13inactivada con betapropiolactona y adyuvada con hidróxido de aluminio. cada mililitro contiene un mínimo de 1 ui de potencia. - suspensión de virus rábico cepa pasteur desarrollada en células bhk 21 don 13inactivada con betapropiolactona y adyuvada con hidróxido de aluminio. cada mililitro contiene un mínimo de 1 ui de potencia. - bovinos

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infecciones por vih - antivirales para uso sistémico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica, s.a. - risperidona - excipientes: hidrogenofosfato disodico dodecahidratado,cloruro de sodio - antipsicÓticos - otros antipsicóticos - risperidona

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bexal farmaceutica, s.a - risperidona - excipientes: cloruro de sodio,hidrogenofosfato disodico dodecahidratado - antipsicÓticos - otros antipsicóticos - risperidona

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

reckitt benckiser healthcare s.a. - salicilato metilo; alcanfor; esencia trementina; mentol - soluciÓn para pulverizaciÓn cutÁnea - 25 mg/ml + 40 mg/ml + 65 mg/ml + 40 mg/ml - salicilato metilo 25 mg; alcanfor 40 mg; esencia trementina 65 mg; mentol 40 mg - preparados con ácido salicílico y derivados